Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Nutrients|November 25, 2023
Curly Kale (<i>Brassica oleracea var. Sabellica</i> L.) Biofortified with 5,7-Diiodo-8-quinolinol: The Influence of Heat Treatment on Iodine Level, Macronutrient Composition and Antioxidant ContentJustyna Waśniowska, Teresa Leszczyńska, Aneta Kopeć, et al.
Plos One|June 4, 2021
The interplay of seizures-induced axonal sprouting and transcription-dependent Bdnf repositioning in the model of temporal lobe epilepsyAnna Skupien-Jaroszek, Agnieszka Walczak, Iwona Czaban, et al.
Peerj|February 24, 2017
ToxGen: an improved reference database for the identification of type B-trichothecene genotypes in <i>Fusarium</i>Tomasz Kulik, Kessy Abarenkov, Maciej Buśko, et al.
Scientific Reports|October 31, 2025
Poly(A) tail dynamics, non-adenine incorporation and alternative polyadenylation shape the host transcriptome in COVID-19 pathogenesisMateusz A Maździarz, Katarzyna Krawczyk, Ewa Lepiarczyk, et al.
Computers in Biology and Medicine|November 5, 2024
SARS-CoV-2 disrupts host gene networks: Unveiling key hub genes as potential therapeutic targets for COVID-19 managementMarta Majewska, Mateusz Maździarz, Katarzyna Krawczyk, et al.
Scientific Reports|December 2, 2025
Antimicrobial activity of silver free powder coatings based on biocomponentsKatarzyna Krawczyk, Barbara Pilch-Pitera, Michał Kędzierski, et al.
Materials (Basel, Switzerland)|December 11, 2025
Study on Antibacterial Powder Coatings Based on Halloysite/Biopolymer CompoundsKatarzyna Krawczyk, Barbara Pilch-Pitera, Michał Kędzierski, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinasesMagdalena Sieprawska-Lupa, Piotr Mydel, Katarzyna Krawczyk, et al.
The New Phytologist|February 10, 2025
Evolution of sexual systems and regressive evolution in RicciaJonathan Levins, Łukasz Paukszto, Katarzyna Krawczyk, et al.
Leukemia & Lymphoma|April 10, 2019
Consolidation with <sup>90</sup>Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-upWojciech Jurczak, Alicja M Gruszka, Anna Sowa Staszczak, et al.
Pageof 6